Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer

OBJECTIVES: To quantify the dose-response relationship of changes in pelvic bone marrow (PBM) functional MR radiomic features (RF) during concurrent chemoradiotherapy (CCRT) for patients with cervical cancer and establish the correlation with hematologic toxicity to provide a basis for PBM sparing....

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Xiaohang, Wang, Cong, Gong, Guanzhong, Wang, Lizhen, Su, Ya, Yin, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644624/
https://www.ncbi.nlm.nih.gov/pubmed/36348290
http://dx.doi.org/10.1186/s12885-022-10254-7
_version_ 1784826782450450432
author Qin, Xiaohang
Wang, Cong
Gong, Guanzhong
Wang, Lizhen
Su, Ya
Yin, Yong
author_facet Qin, Xiaohang
Wang, Cong
Gong, Guanzhong
Wang, Lizhen
Su, Ya
Yin, Yong
author_sort Qin, Xiaohang
collection PubMed
description OBJECTIVES: To quantify the dose-response relationship of changes in pelvic bone marrow (PBM) functional MR radiomic features (RF) during concurrent chemoradiotherapy (CCRT) for patients with cervical cancer and establish the correlation with hematologic toxicity to provide a basis for PBM sparing. METHODS: A total of 54 cervical cancer patients who received CCRT were studied retrospectively. Patients underwent MRI IDEAL IQ and T2 fat suppression (T2fs) scanning pre- and post-CCRT. The PBM RFs were extracted from each region of interest at dose gradients of 5–10 Gy, 10–15 Gy, 15–20 Gy, 20–30 Gy, 30–40 Gy, 40–50 Gy, and > 50 Gy, and changes in peripheral blood cell (PBC) counts during radiotherapy were assessed. The dose-response relationship of RF changes and their correlation with PBC changes were investigated. RESULTS: White blood cell, neutrophils (ANC) and lymphocyte counts during treatment were decreased by 49.4%, 41.4%, and 76.3%, respectively. Most firstorder features exhibited a significant dose-response relationship, particularly FatFrac IDEAL IQ, which had a maximum dose-response curve slope of 10.09, and WATER IDEAL IQ had a slope of − 7.93. The firstorder-Range in FAT IDEAL IQ and firstorder-10Percentile in T2fs, showed a significant correlation between the changes in ANC counts under the low dose gradient of 5–10 Gy (r = 0.744, -0.654, respectively, p < 0.05). CONCLUSION: Functional MR radiomics can detect microscopic changes in PBM at various dose gradients and provide an objective reference for bone marrow sparing and dose limitation in cervical cancer CCRT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10254-7.
format Online
Article
Text
id pubmed-9644624
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96446242022-11-15 Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer Qin, Xiaohang Wang, Cong Gong, Guanzhong Wang, Lizhen Su, Ya Yin, Yong BMC Cancer Research OBJECTIVES: To quantify the dose-response relationship of changes in pelvic bone marrow (PBM) functional MR radiomic features (RF) during concurrent chemoradiotherapy (CCRT) for patients with cervical cancer and establish the correlation with hematologic toxicity to provide a basis for PBM sparing. METHODS: A total of 54 cervical cancer patients who received CCRT were studied retrospectively. Patients underwent MRI IDEAL IQ and T2 fat suppression (T2fs) scanning pre- and post-CCRT. The PBM RFs were extracted from each region of interest at dose gradients of 5–10 Gy, 10–15 Gy, 15–20 Gy, 20–30 Gy, 30–40 Gy, 40–50 Gy, and > 50 Gy, and changes in peripheral blood cell (PBC) counts during radiotherapy were assessed. The dose-response relationship of RF changes and their correlation with PBC changes were investigated. RESULTS: White blood cell, neutrophils (ANC) and lymphocyte counts during treatment were decreased by 49.4%, 41.4%, and 76.3%, respectively. Most firstorder features exhibited a significant dose-response relationship, particularly FatFrac IDEAL IQ, which had a maximum dose-response curve slope of 10.09, and WATER IDEAL IQ had a slope of − 7.93. The firstorder-Range in FAT IDEAL IQ and firstorder-10Percentile in T2fs, showed a significant correlation between the changes in ANC counts under the low dose gradient of 5–10 Gy (r = 0.744, -0.654, respectively, p < 0.05). CONCLUSION: Functional MR radiomics can detect microscopic changes in PBM at various dose gradients and provide an objective reference for bone marrow sparing and dose limitation in cervical cancer CCRT. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10254-7. BioMed Central 2022-11-08 /pmc/articles/PMC9644624/ /pubmed/36348290 http://dx.doi.org/10.1186/s12885-022-10254-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Qin, Xiaohang
Wang, Cong
Gong, Guanzhong
Wang, Lizhen
Su, Ya
Yin, Yong
Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
title Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
title_full Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
title_fullStr Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
title_full_unstemmed Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
title_short Functional MRI radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
title_sort functional mri radiomics-based assessment of pelvic bone marrow changes after concurrent chemoradiotherapy for cervical cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644624/
https://www.ncbi.nlm.nih.gov/pubmed/36348290
http://dx.doi.org/10.1186/s12885-022-10254-7
work_keys_str_mv AT qinxiaohang functionalmriradiomicsbasedassessmentofpelvicbonemarrowchangesafterconcurrentchemoradiotherapyforcervicalcancer
AT wangcong functionalmriradiomicsbasedassessmentofpelvicbonemarrowchangesafterconcurrentchemoradiotherapyforcervicalcancer
AT gongguanzhong functionalmriradiomicsbasedassessmentofpelvicbonemarrowchangesafterconcurrentchemoradiotherapyforcervicalcancer
AT wanglizhen functionalmriradiomicsbasedassessmentofpelvicbonemarrowchangesafterconcurrentchemoradiotherapyforcervicalcancer
AT suya functionalmriradiomicsbasedassessmentofpelvicbonemarrowchangesafterconcurrentchemoradiotherapyforcervicalcancer
AT yinyong functionalmriradiomicsbasedassessmentofpelvicbonemarrowchangesafterconcurrentchemoradiotherapyforcervicalcancer